KRYSKrystal Biotech, Inc.

Price: $306.73 | Today's Change: -7.68%

What Happened

Krystal Biotech filed an 8-K with the SEC on November 2, 2026, reporting its third-quarter fiscal 2026 financial results (Items 2.02 and 9.01). The company posted revenue of $282.0 million for Q3 FY2026, alongside operating income of $117.0 million, representing a substantial operating performance for the period. Net income came in at $35.7 million, with basic earnings per share of $5.31 and diluted earnings per share of $5.14.

Why It Matters

The headline numbers reflect a company generating meaningful top-line revenue and strong operating income, yet the gap between operating income ($117M) and net income ($35.7M) is notable — suggesting significant below-the-line charges, such as taxes, interest expenses, or other non-operating items, materially reduced net profitability in the quarter. This divergence is something investors will want to scrutinize closely. Despite solid operational execution, the stock is down 7.68% on the day, indicating the market may have had higher expectations or is reacting to items not directly captured in the XBRL-extracted figures provided here. StockWatch initiated coverage of KRYS on September 4, 2026, and this quarterly result represents the first major earnings data point since that initiation.

Analysis

The Q3 FY2026 results present a mixed picture. On one hand, $282 million in quarterly revenue and $117 million in operating income point to a commercial-stage biotech with genuine, scaled product economics — a profile that remains relatively rare in the sector. The diluted EPS of $5.14 is a meaningful absolute figure. On the other hand, the sharp reduction from operating income to net income warrants attention: investors and analysts will be looking carefully at the components below the operating line when the full financial statements become available via the attached exhibit (9.01).

The market's negative reaction — shares off more than 7% — likely signals that either the top-line figure missed consensus expectations, guidance was disappointing, or commentary accompanying the release raised concerns. None of those contextual details are available in the structured XBRL data alone, so readers should consult the full earnings release attached to this filing for management's commentary and any forward-looking statements.

Key items to watch going forward:

• The reconciliation between operating and net income — understanding what drove the ~$81M gap will be critical.
• Revenue trajectory — whether the $282M quarterly run-rate is accelerating, decelerating, or in line with prior guidance.
• Management's forward outlook — any updated guidance or pipeline commentary disclosed in the accompanying press release.

Disclaimer

This report is a news and informational summary based solely on data extracted from Krystal Biotech's SEC filing dated November 2, 2026. It does not constitute investment advice, a solicitation to buy or sell securities, or an equity research recommendation. No rating or price target is issued in this report. Investors should conduct their own due diligence and consult a qualified financial advisor before making investment decisions.

Existing Coverage

StockWatch has full coverage on KRYS, published 2026-09-04. Read our Initiating Coverage →

Source

Filed with the SEC on 2026-11-02. Read the original filing on EDGAR: https://www.sec.gov/Archives/edgar/data/1711279/000171127926000072/krys-20261102.htm